{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:48:22Z","timestamp":1790264902583,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01151-5","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T17:12:13Z","timestamp":1762794733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development, Verification, and Application of a Chinese Pediatric Physiologically Based Pharmacokinetic Model: Emphasis on CYP Metabolism and Renal Elimination"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4941-2829","authenticated-orcid":false,"given":"Rosalind L.","family":"Southall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3255-8925","authenticated-orcid":false,"given":"Jean","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2418-5970","authenticated-orcid":false,"given":"Xian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-0081","authenticated-orcid":false,"given":"Trevor N.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"1","key":"1151_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","volume":"108","author":"M Grimstein","year":"2019","unstructured":"Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. food and drug administration\u2019s office of clinical pharmacology. J Pharm Sci. 2019;108(1):21\u20135. https:\/\/doi.org\/10.1016\/j.xphs.2018.10.033.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1151_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/psp4.12479","volume":"9","author":"C Kuemmel","year":"2020","unstructured":"Kuemmel C, Yang Y, Zhang X, Florian J, Zhu H, Tegenge M, et al. Consideration of a credibility assessment framework in model-informed drug development: potential application to physiologically-based pharmacokinetic modeling and simulation. CPT: Pharmacometrics & Systems Pharmacology. 2020;9(1):21\u20138. https:\/\/doi.org\/10.1002\/psp4.12479.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"2","key":"1151_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4155\/ipk-2016-0025","volume":"2","author":"S Cole","year":"2017","unstructured":"Cole S, Han LH, Luzon E, Nordmark A, Skottheim RI. European Regulatory Perspective on Pediatric Physiologically Based Pharmacokinetic Models. Int J Pharmacokinet. 2017;2(2):113\u201324. https:\/\/doi.org\/10.4155\/ipk-2016-0025.","journal-title":"Int J Pharmacokinet"},{"issue":"4","key":"1151_CR4","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/cts.12987","volume":"14","author":"W Tang","year":"2021","unstructured":"Tang W, Huang Y, Zhou D, Huang Y, Chen Y, Ren S, et al. Evolving drug regulatory landscape in China: a clinical pharmacology perspective. Clin Transl Sci. 2021;14(4):1222\u201330. https:\/\/doi.org\/10.1111\/cts.12987.","journal-title":"Clin Transl Sci"},{"key":"1151_CR5","unstructured":"European Medicines Agency. ICH Topic E5 (R1) Ethnic factors in the acceptability of foreign clinical data - Scientific guideline. https:\/\/www.ema.europa.eu\/en\/ich-e5-r1-ethnic-factors-acceptability-foreign-clinical-data-scientific-guideline (1998). Accessed 21 Aug 2025."},{"issue":"7","key":"1151_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40262-015-0356-1","volume":"55","author":"S Feng","year":"2016","unstructured":"Feng S, Shi J, Parrott N, Hu P, Weber C, Martin-Facklam M, et al. Combining \u201cbottom-up\u201d and \u201ctop-down\u201d methods to assess ethnic difference in clearance: Bitopertin as an example. Clin Pharmacokinet. 2016;55(7):823\u201332. https:\/\/doi.org\/10.1007\/s40262-015-0356-1.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1151_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/00498250600683262","volume":"36","author":"S Inoue","year":"2006","unstructured":"Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, et al. Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica. 2006;36(6):499\u2013513. https:\/\/doi.org\/10.1080\/00498250600683262.","journal-title":"Xenobiotica"},{"issue":"12","key":"1151_CR8","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","volume":"52","author":"ZE Barter","year":"2013","unstructured":"Barter ZE, Tucker GT, Rowland-Yeo K. Differences in cytochrome P450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2013;52(12):1085\u2013100. https:\/\/doi.org\/10.1007\/s40262-013-0089-y.","journal-title":"Clin Pharmacokinet"},{"issue":"3\u20134","key":"1151_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/bdd.2178","volume":"40","author":"Y Kim","year":"2019","unstructured":"Kim Y, Hatley O, Rhee SJ, Yi S, Lee HA, Yoon S, et al. Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation. Biopharm Drug Dispos. 2019;40(3\u20134):135\u201350. https:\/\/doi.org\/10.1002\/bdd.2178.","journal-title":"Biopharm Drug Dispos"},{"issue":"12","key":"1151_CR10","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/psp4.12716","volume":"10","author":"M Zhao","year":"2021","unstructured":"Zhao M, Chen Y, Yang D, Lyu C, Bian X, Li X, et al. Regulatory utility of pharmacometrics in the development and evaluation of antimicrobial agents and its recent progress in China. CPT: Pharmacometrics & Systems Pharmacology. 2021;10(12):1466\u201378. https:\/\/doi.org\/10.1002\/psp4.12716.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"9","key":"1151_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931\u201356. https:\/\/doi.org\/10.2165\/00003088-200645090-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1151_CR12","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/jcph.2317","volume":"63","author":"TN Johnson","year":"2023","unstructured":"Johnson TN, Abduljalil K, Pan X, Emoto C. Development and verification of a Japanese pediatric physiologically based pharmacokinetic model with emphasis on drugs eliminated by cytochrome P450 or renal excretion. J Clin Pharmacol. 2023;63(10):1156\u201368. https:\/\/doi.org\/10.1002\/jcph.2317.","journal-title":"J Clin Pharmacol"},{"key":"1151_CR13","doi-asserted-by":"publisher","first-page":"648697","DOI":"10.3389\/fphar.2021.648697","volume":"12","author":"X Yao","year":"2021","unstructured":"Yao X, Liu X, Tu S, Li X, Lei Z, Hou Z, et al. Development of a virtual Chinese pediatric population physiological model targeting specific metabolism and kidney elimination pathways. Front Pharmacol. 2021;12:648697. https:\/\/doi.org\/10.3389\/fphar.2021.648697.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1151_CR14","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/cpt.3409","volume":"116","author":"A Thakur","year":"2024","unstructured":"Thakur A, Subash S, Ahire D, Prasad B. Developmental expression of drug transporters and conjugating enzymes involved in enterohepatic recycling: implication for pediatric drug dosing. Clin Pharmacol Ther. 2024;116(6):1615\u201326. https:\/\/doi.org\/10.1002\/cpt.3409.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1151_CR15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/jcph.2452","volume":"64","author":"M Codaccioni","year":"2024","unstructured":"Codaccioni M, Southall RL, Dinh J, Johnson TN. Prediction of pediatric pharmacokinetics for CYP3A4 metabolized drugs: comparison of the performance of two hepatic ontogeny within a physiologically based pharmacokinetic model. J Clin Pharmacol. 2024;64(9):1083\u201394. https:\/\/doi.org\/10.1002\/jcph.2452.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1151_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/psp4.12203","volume":"6","author":"M Sato","year":"2017","unstructured":"Sato M, Ochiai Y, Kijima S, Nagai N, Ando Y, Shikano M, et al. Quantitative modeling and simulation in PMDA: a Japanese regulatory perspective. CPT Pharmacometrics Syst Pharmacol. 2017;6(7):413\u20135. https:\/\/doi.org\/10.1002\/psp4.12203.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"Suppl 1","key":"1151_CR17","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1002\/jcph.1767","volume":"60","author":"X Zhang","year":"2020","unstructured":"Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM, et al. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018\u20132019 submissions to the US FDA\u2019s office of clinical pharmacology. J Clin Pharmacol. 2020;60(Suppl 1):S160-78. https:\/\/doi.org\/10.1002\/jcph.1767.","journal-title":"J Clin Pharmacol"},{"key":"1151_CR18","unstructured":"European Medicines Agency. ICH guideline E11A on pediatric extrapolation - scientific guideline. https:\/\/www.ema.europa.eu\/en\/ich-guideline-e11a-pediatric-extrapolation-scientific-guideline (2022). Accessed 25 Jan 2025."},{"issue":"2","key":"1151_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bcpt.13209","volume":"125","author":"L Zhou","year":"2019","unstructured":"Zhou L, Tong X, Sharma P, Xu H, Al-Huniti N, Zhou D. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study. Basic Clin Pharmacol Toxicol. 2019;125(2):100\u20137. https:\/\/doi.org\/10.1111\/bcpt.13209.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"1151_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/psp4.12279","volume":"7","author":"C Emoto","year":"2018","unstructured":"Emoto C, Johnson TN, McPhail BT, Vinks AA, Fukuda T. Using a vancomycin PBPK model in special populations to elucidate case-based clinical PK observations. CPT: Pharmacometrics & Systems Pharmacology. 2018;7(4):237\u201350. https:\/\/doi.org\/10.1002\/psp4.12279.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"7","key":"1151_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40262-014-0140-7","volume":"53","author":"F Salem","year":"2014","unstructured":"Salem F, Johnson TN, Abduljalil K, Tucker GT, Rostami-Hodjegan A. A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet. 2014;53(7):625\u201336. https:\/\/doi.org\/10.1007\/s40262-014-0140-7.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1151_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/jcph.585","volume":"56","author":"VV Upreti","year":"2016","unstructured":"Upreti VV, Wahlstrom JL. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56(3):266\u201383. https:\/\/doi.org\/10.1002\/jcph.585.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1151_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1124\/dmd.118.083642","volume":"47","author":"H Shimizu","year":"2019","unstructured":"Shimizu H, Yoshida K, Nakada T, Kojima K, Ogasawara A, Nakamaru Y, et al. Prediction of human distribution volumes of compounds in various elimination phases using physiologically based pharmacokinetic modeling and experimental pharmacokinetics in animals. Drug Metab Dispos. 2019;47(2):114\u201323. https:\/\/doi.org\/10.1124\/dmd.118.083642.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"1151_CR24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40262-019-00737-5","volume":"58","author":"GF Li","year":"2019","unstructured":"Li GF, Zheng QS, Yu Y, Zhong W, Zhou HH, Qiu F, et al. Impact of ethnicity-specific hepatic microsomal scaling factor, liver weight, and cytochrome P450 (CYP) 1A2 content on physiologically based prediction of CYP1A2-mediated pharmacokinetics in young and elderly Chinese adults. Clin Pharmacokinet. 2019;58(7):927\u201341. https:\/\/doi.org\/10.1007\/s40262-019-00737-5.","journal-title":"Clin Pharmacokinet"},{"key":"1151_CR25","unstructured":"U.S. Food & Drug Administration. SUSTIVA (efavirenz) capsules for oral use. SUSTIVA (efavirenz) tablets for oral use. [package insert]. Bristol- Myers Squibb Company. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020972s057,021360s045lbl.pdf (2019). Accessed 21 Aug 2025."},{"key":"1151_CR26","unstructured":"World Health Organisation. Antiretroviral therapy of HIVinfection in infants and children: towards universal access: recommendations for a public health approach \u2013 2010 revision. https:\/\/iris.who.int\/handle\/10665\/164255 (2010). Accessed 21 Aug 2025."},{"key":"1151_CR27","unstructured":"European Medicines Agency. ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population - Scientific guideline. https:\/\/www.ema.europa.eu\/en\/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-scientific-guideline (2017). Accessed 21 Aug 2025."},{"issue":"1","key":"1151_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/clpt.1990.111","volume":"48","author":"HH Zhou","year":"1990","unstructured":"Zhou HH, Adedoyin A, Wilkinson GR. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther. 1990;48(1):10\u20137. https:\/\/doi.org\/10.1038\/clpt.1990.111.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1151_CR29","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1124\/dmd.108.021311","volume":"36","author":"ZE Barter","year":"2008","unstructured":"Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos. 2008;36(12):2405\u20139. https:\/\/doi.org\/10.1124\/dmd.108.021311.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1151_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1124\/dmd.121.000623","volume":"50","author":"JS Leeder","year":"2022","unstructured":"Leeder JS, Dinh JC, Gaedigk A, Staggs VS, Prasad B, Pearce RE. Ontogeny of scaling factors for pediatric physiology-based pharmacokinetic modeling and simulation: microsomal protein per gram of liver. Drug Metab Dispos. 2022;50(1):24\u201332. https:\/\/doi.org\/10.1124\/dmd.121.000623.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1151_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.clpt.2006.03.010","volume":"80","author":"KK Loboz","year":"2006","unstructured":"Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006;80(1):75\u201384. https:\/\/doi.org\/10.1016\/j.clpt.2006.03.010.","journal-title":"Clin Pharmacol Ther"},{"issue":"4 Pt 1","key":"1151_CR32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1203\/00006450-198104000-00003","volume":"15","author":"M Bonati","year":"1981","unstructured":"Bonati M, Latini R, Marra G, Assael BM, Parini R. Theophylline metabolism during the first month of life and development. Pediatr Res. 1981;15(4 Pt 1):304\u20138. https:\/\/doi.org\/10.1203\/00006450-198104000-00003.","journal-title":"Pediatr Res"},{"key":"1151_CR33","doi-asserted-by":"publisher","first-page":"840710","DOI":"10.3389\/fped.2022.840710","volume":"10","author":"K Abduljalil","year":"2022","unstructured":"Abduljalil K, Gardner I, Jamei M. Application of a physiologically based pharmacokinetic approach to predict theophylline pharmacokinetics using virtual non-pregnant, pregnant, fetal, breast-feeding, and neonatal populations. Front Pediatr. 2022;10:840710. https:\/\/doi.org\/10.3389\/fped.2022.840710.","journal-title":"Front Pediatr"},{"issue":"6","key":"1151_CR34","first-page":"399","volume":"35","author":"DTWY Ren","year":"1998","unstructured":"Ren DTWY, Shen J, Wang J. Study on pharmacokinetics of theophylline in different groups of infants [Article in Chinese]. Chin Pharm J. 1998;35(6):399\u2013400.","journal-title":"Chin Pharm J"},{"key":"1151_CR35","first-page":"534","volume":"12","author":"J Wang","year":"1995","unstructured":"Wang J, Ren DT, Shen J, Liang WQ. Study on pharmacokinetics of theophylline on neonates. [Article in Chinese]. Chin J Hosp Pharm. 1995;12:534\u20136.","journal-title":"Chin J Hosp Pharm"},{"key":"1151_CR36","unstructured":"Chen Z, Zhang Z, Chen Y. \u54ee\u5598\u513f\u7ae5\u8336\u78b1\u4ee3\u8c22\u52a8\u529b\u5b66\u53ca\u4e34\u5e8a\u5e94\u7528 [Article in Chinese]. Chin J Clin Pharmacol. 1989;5(2):97-101."},{"issue":"23","key":"1151_CR37","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1039\/d2ay00533f","volume":"14","author":"Z Li","year":"2022","unstructured":"Li Z, Sun N, Zhang Q, Ma HH, Wang D, Zhao YZ, et al. Development and application of an LC-MS\/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis. Anal Methods. 2022;14(23):2293\u2013303. https:\/\/doi.org\/10.1039\/d2ay00533f.","journal-title":"Anal Methods"},{"issue":"16","key":"1151_CR38","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.7150\/ijms.65040","volume":"18","author":"Y Yu","year":"2021","unstructured":"Yu Y, Lin J, Muto C, Li Y, Mori Y, Mittapalli RK, et al. Assessment of the utility of physiologically-based pharmacokinetic model for prediction of pharmacokinetics in Chinese and Japanese populations. Int J Med Sci. 2021;18(16):3718\u201327. https:\/\/doi.org\/10.7150\/ijms.65040.","journal-title":"Int J Med Sci"},{"key":"1151_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106587","volume":"191","author":"Y Jin","year":"2023","unstructured":"Jin Y, Zhang M, Di X, Qi X, Zheng L, Wang Z. Comparison of intravenous ibuprofen pharmacokinetics between Caucasian and Chinese populations using physiologically based pharmacokinetics modeling and simulation. Eur J Pharm Sci. 2023;191:106587. https:\/\/doi.org\/10.1016\/j.ejps.2023.106587.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"1151_CR40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1248\/bpb.32.304","volume":"32","author":"T Igarashi","year":"2009","unstructured":"Igarashi T, Iwakawa S. Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. Biol Pharm Bull. 2009;32(2):304\u20137. https:\/\/doi.org\/10.1248\/bpb.32.304.","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"1151_CR41","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/cpt.2912","volume":"114","author":"X Pan","year":"2023","unstructured":"Pan X, Rowland Yeo K. Physiologically based pharmacokinetic modeling to determine the impact of CYP2B6 genotype on Efavirenz exposure in children, mothers and breastfeeding infants. Clin Pharmacol Ther. 2023;114(1):182\u201391. https:\/\/doi.org\/10.1002\/cpt.2912.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1151_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2019-000618","volume":"4","author":"GX Hao","year":"2020","unstructured":"Hao GX, Yuan XX, Guo W, Quan XY, Qi XJ, Wang TY, et al. Paediatric drugs trials in China. BMJ Paediatrics Open. 2020;4(1):e000618. https:\/\/doi.org\/10.1136\/bmjpo-2019-000618.","journal-title":"BMJ Paediatrics Open"},{"key":"1151_CR43","unstructured":"Center for Drug Evaluation NMPA. \u751f\u7406\u836f\u4ee3\u52a8\u529b\u5b66\u6a21\u578b\u5728\u513f\u79d1\u4eba\u7fa4\u836f\u7269\u7814\u53d1\u4e2d\u5e94\u7528\u7684\u6280\u672f\u6307\u5bfc\u539f\u5219 [Document in Chinese]. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/c1ccd4f7d92531ead702938347b75874 (2023). Accessed 21 Aug 2025."},{"key":"1151_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2022-001666","author":"Y Geng","year":"2023","unstructured":"Geng Y, Li Q, Sun YZ, Zhang H, Jiang YL, Wang LQ, et al. Regulatory considerations for paediatric drug evaluation in China. BMJ Paediatrics Open. 2023. https:\/\/doi.org\/10.1136\/bmjpo-2022-001666.","journal-title":"BMJ Paediatrics Open"},{"key":"1151_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70004","author":"D Yang","year":"2025","unstructured":"Yang D, Li J, Mak WY, Zheng A, Zhu X, He Q, et al. PBPK modeling: empowering drug development and precision dosing in China. CPT: Pharmacometrics & Systems Pharmacology. 2025. https:\/\/doi.org\/10.1002\/psp4.70004.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"1151_CR46","first-page":"548","volume":"2","author":"J Li","year":"2013","unstructured":"Li J, Xu D, Gao X. Comparative study of the pharmacokinetics of fentanyl citrate spianl anesthesia in patients with different ages [Article in Chinese]. China Health Care Nutr. 2013;2:548\u20139.","journal-title":"China Health Care Nutr"},{"key":"1151_CR47","first-page":"18","volume":"1","author":"K Xu","year":"2001","unstructured":"Xu K, Yue J, Chen S, Guo P, Yang Z. Pharmacokinetics of fentanyl in patients of different ages undergoing non-cardiac surgery [Article in Chinese]. Chin J Anesthesiol. 2001;1:18\u201320.","journal-title":"Chin J Anesthesiol"},{"issue":"3","key":"1151_CR48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/bja\/70.3.286","volume":"70","author":"RD Jones","year":"1993","unstructured":"Jones RD, Chan K, Roulson CJ, Brown AG, Smith ID, Mya GH. Pharmacokinetics of flumazenil and midazolam. Br J Anaesth. 1993;70(3):286\u201392. https:\/\/doi.org\/10.1093\/bja\/70.3.286.","journal-title":"Br J Anaesth"},{"issue":"9","key":"1151_CR49","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/phar.1988","volume":"37","author":"X Liu","year":"2017","unstructured":"Liu X, Ma Q, Zhao Y, Mu W, Sun X, Cheng Y, et al. Impact of single nucleotide polymorphisms on plasma concentrations of efavirenz and lopinavir\/ritonavir in Chinese children infected with the human immunodeficiency virus. Pharmacotherapy. 2017;37(9):1073\u201380. https:\/\/doi.org\/10.1002\/phar.1988.","journal-title":"Pharmacotherapy"},{"key":"1151_CR50","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02486-17","author":"ZR Shi","year":"2018","unstructured":"Shi ZR, Chen XK, Tian LY, Wang YK, Zhang GY, Dong L, et al. Population pharmacokinetics and dosing optimization of ceftazidime in infants. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.02486-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1151_CR51","first-page":"133","volume":"34","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Chen M, Li B. Serum concentration monitoring and pharmacokinetics characters of vancomycin in child patients from pediatric intensive care unit. [Article in Chinese]. Chin J New Drugs Clin Rem. 2015;34(2):133\u20136.","journal-title":"Chin J New Drugs Clin Rem"},{"issue":"6","key":"1151_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/jcph.653","volume":"56","author":"H Zhang","year":"2016","unstructured":"Zhang H, Wang Y, Gao P, Hu J, Chen Y, Zhang L, et al. Pharmacokinetic characteristics and clinical outcomes of vancomycin in young children with various degrees of renal function. J Clin Pharmacol. 2016;56(6):740\u20138. https:\/\/doi.org\/10.1002\/jcph.653.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1151_CR53","first-page":"487","volume":"47","author":"H Li","year":"2009","unstructured":"Li H, Ji CY, Zong XN, Zhang YQ. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years. Zhonghua Er Ke Za Zhi. 2009;47(7):487\u201392.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"1","key":"1151_CR54","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/s0022-3476(78)80601-5","volume":"93","author":"GB Haycock","year":"1978","unstructured":"Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93(1):62\u20136. https:\/\/doi.org\/10.1016\/s0022-3476(78)80601-5.","journal-title":"J Pediatr"},{"issue":"5","key":"1151_CR55","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutr. 1989;5(5):303\u201311 (discussion 12-3).","journal-title":"Nutr"},{"issue":"9","key":"1151_CR56","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1097\/CCM.0b013e3181e8adee","volume":"38","author":"GN Cattermole","year":"2010","unstructured":"Cattermole GN, Leung PY, Mak PS, Chan SS, Graham CA, Rainer TH. The normal ranges of cardiovascular parameters in children measured using the ultrasonic cardiac output monitor. Crit Care Med. 2010;38(9):1875\u201381. https:\/\/doi.org\/10.1097\/CCM.0b013e3181e8adee.","journal-title":"Crit Care Med"},{"issue":"5","key":"1151_CR57","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1097\/PCC.0b013e3182772f78","volume":"14","author":"GY Ho","year":"2013","unstructured":"Ho GY, Cattermole GN, Chan SS, Smith BE, Graham CA, Rainer TH. Noninvasive transcutaneous Doppler ultrasound-derived hemodynamic reference ranges in Chinese adolescents. Pediatr Crit Care Med. 2013;14(5):e225\u201332. https:\/\/doi.org\/10.1097\/PCC.0b013e3182772f78.","journal-title":"Pediatr Crit Care Med"},{"key":"1151_CR58","unstructured":"Xu NJ, Yuanyuan XJ. 6~8\u5c81\u513f\u7ae5\u5fc3\u80ba\u529f\u80fd\u53d1\u80b2\u60c5\u51b5\u8c03\u67e5\u53ca\u5176\u4e0e\u4f53\u578b\u53d8\u5316 [Article in Chinese]. \u4e2d\u56fd\u751f\u80b2\u5065\u5eb7\u6742\u5fd7 2019;30(5):440\u20138."},{"key":"1151_CR59","unstructured":"Chang H, Ni J. \u540d\u5b66\u9f84\u513f\u7ae5\u8840\u6db2\u52a8\u529b\u6d41\u53d8\u5b66\u53c2\u6570\u7684\u68c0\u6d4b. [Article in Chinese]. \u4e2d\u534e\u513f\u7ae5\u4fdd\u5065\u6742\u5fd7 1995;3(4):283\u20134."},{"issue":"9","key":"1151_CR60","first-page":"774","volume":"43","author":"H Qi","year":"2015","unstructured":"Qi H, Xu S, Ma R, Jiang L, Li S, Mai S, et al. Comparison of echocardiographic parameters in healthy Chinese children born and living at high altitude or at sea-level] [Article in Chinese. Zhonghua Xin Xue Guan Bing Za Zhi. 2015;43(9):774\u201381.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"1151_CR61","unstructured":"Huang C, Wang B. 9\u201315\u5c81\u7537\u5973\u5b69\u5fc3\u8f93\u51fa\u91cf, VO2max \u4e0e\u65e0\u6c27\u548c\u6709\u6c27\u8fd0\u52a8\u80fd\u529b\u7814\u7a76. [Article in Chinese]. \u76ca\u9633\u5e08\u4e13\u5b66\u62a5(\u81ea\u7136\u79d1\u5b66\u7248). 1989;(2):15\u201337."},{"key":"1151_CR62","unstructured":"Hu P, Qin Y, Jing C, Li. M, Lei F. \u4e0d\u540c\u6027\u522b\u3001\u5e74\u9f84\u7ec4\u513f\u7ae5\u80be\u5c0f\u7403\u6ee4\u8fc7\u7387\u5206\u5e03\u60c5\u51b5. [Article in Chinese]. J Appl Clin Pediatr. 2007;22(23):1803\u20134."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01151-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01151-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01151-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:20:32Z","timestamp":1770826832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01151-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01151-5","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RS, JD, XP, JN, and TNJ are employees and may be shareholders of Certara UK Limited (Certara\u00a0Predictive Technologies Division).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"17"}}